FIRMQUARRYResearch workspace

GOVERNMENT CONTRACT / PURCHASE ORDER

IMMUNOPROTEOMIC PROFILING OF ANTIBODIES AGAINST EPSTEIN-BARR VIRUS IN GASTRIC CANCER AND PREMALIGNANT LESIONS IN SUPPORT OF HHS, NIH, NCI, DCEG, IIB

Awarded to ARIZONA STATE UNIVERSITY

PIID 75N91021P00598US · USAspendingOther
$38K
Data last updated Oct 22, 2026 · Source: USAspending
Transaction obligation$38,000sum disclosed on award record
Current contract valueNot reportednot interchangeable with obligation
Potential contract valueNot reportedincluding options if reported
Award dateJul 16, 2021
Company legal name
ARIZONA STATE UNIVERSITY
UEI / CAGE
HX59VKHQH1V7 / Not reported
Parent award
Not reported
Awarding agency
Department of Health and Human Services
Subagency
National Institutes of Health
Industry
Other
NAICS
541380
PSC
Q301
Performance period
Not reported — Not reported
Recipient address
300 E UNIVERSITY DR STE 410, TEMPE, MARICOPA, AZ, 85281
Place of performance
TEMPE, MARICOPA, AZ, 85281
Source last modified
Nov 3, 2026

Description

IMMUNOPROTEOMIC PROFILING OF ANTIBODIES AGAINST EPSTEIN-BARR VIRUS IN GASTRIC CANCER AND PREMALIGNANT LESIONS IN SUPPORT OF HHS, NIH, NCI, DCEG, IIB

View federal source ↗

Derived from official transactions

Contract lifecycle

  1. Award announced

    IMMUNOPROTEOMIC PROFILING OF ANTIBODIES AGAINST EPSTEIN-BARR VIRUS IN GASTRIC CANCER AND PREMALIGNANT LESIONS IN SUPPORT OF HHS, NIH, NCI, DCEG, IIB

    US · usaspendingSource ↗
  2. Value increased

    IMMUNOPROTEOMIC PROFILING OF ANTIBODIES AGAINST EPSTEIN-BARR VIRUS IN GASTRIC CANCER AND PREMALIGNANT LESIONS IN SUPPORT OF HHS, NIH, NCI, DCEG, IIB

    US · usaspending$38KSource ↗

Point-in-time model

Contract change outlook

Predictive intelligenceInsufficient historyNo eligible point-in-time model has produced a prediction for this record.

Uncollapsed source history

Transactions and modifications

Action dateModificationAction typeExact obligationCurrent totalPotential totalDescriptionSource
Jul 16, 20210Not reported$38,000.00Not reportedNot reportedIMMUNOPROTEOMIC PROFILING OF ANTIBODIES AGAINST EPSTEIN-BARR VIRUS IN GASTRIC CANCER AND PREMALIGNANT LESIONS IN SUPPORT OF HHS, NIH, NCI, DCEG, IIBUSAspending ↗
ARIZONA STATE UNIVERSITY: IMMUNOPROTEOMIC PROFILING OF ANTIBODIES AGAINST EPSTEIN-BARR VIRUS IN GASTRIC CA — Government contract | FirmQuarry